- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00728689
Fase I-forsøg med en undersøgelse af koppemedicin
Et fase I randomiseret, dobbeltblindt, crossover, eksplorativt studie af farmakokinetikken af en enkelt oral dosis af form I versus form V kapsler af anti-orthopoxvirusforbindelsen ST-246® i fodrede normale raske frivillige
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.
Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32809
- Orlando Clinical Research Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 to 50 years
- Available for clinical follow-up duration of study.
- Able/willing to give written consent.
- Good general health; no clinically significant medical history.
- Refrain from taking any medications from screening through 72 hours after last dose.
- Adequate venous access.
- PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
- Meet Lab Criteria within 28 days prior to receipt of drug.
- Negative pregnancy test
- Non smokers
- No alcohol or caffeine
- Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study
Exclusion Criteria:
-
Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
-
History of additional risk factors for Torsade de Pointes
-
Clinically significant abnormal ECG
-
Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
-
Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
-
History of any clinically significant conditions including:
- Asthma
- Diabetes mellitus
- History of thyroidectomy or thyroid disease
- Serious angioedema episodes
- Head trauma resulting in a diagnosis of TBI other than concussion
- Seizure or history of seizure
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
- Malignancy
-
Family history of idiopathic seizures
-
History or presence of neutropenia or other blood dyscrasia
-
Known Hepatitis B or Hepatitis C infection
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
-
Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
-
Known clinically significant chronic viral infection (or current clinically significant viral infection
-
History of frequent or severe headaches or migraines
-
Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
-
Woman who is pregnant or is breast-feeding or planning to become pregnant
-
On any concomitant medications
-
History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
-
Inability to swallow medication
-
Body Mass Index above 35 or below 18,
-
Current drug abuse or alcohol abuse.
-
Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
-
Clinically significant lactose intolerance
-
Received experimental drug within 30 days
-
Vaccination within 30 days
-
Total of more than 350 milliliters (mL) of blood drawn in 2 months
-
Treatment with any immunosuppressant or immunomodulatory medication in 3 months
-
Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
-
History or diagnosis that would affect absorption of study medication
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Group ST-246 Form I (followed by Form V)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Andre navne:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Andre navne:
|
|
Aktiv komparator: Group ST-246 Form V (followed by Form I)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Andre navne:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Tidsramme: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Tidsramme: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Tidsramme: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Tidsramme: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax) |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Tidsramme: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Tidsramme: 4 weeks
|
Evaluated safety parameters included:
|
4 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Thomas C Marbury, MD, Orlando Clinical Research Center
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SIGA-246-005
- HHSN266200600014C (Andet bevillings-/finansieringsnummer: NIAID)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .